(CTMX) CytomX Therapeutics - Ratings and Ratios
Antibody-Drug Conjugate, T-Cell Engager, Probody Cytokine, Bispecific Antibody
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 92.5% |
| Value at Risk 5%th | 122% |
| Relative Tail Risk | -19.69% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.57 |
| Alpha | 346.09 |
| CAGR/Max DD | 0.22 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.440 |
| Beta | 2.143 |
| Beta Downside | 1.230 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.59% |
| Mean DD | 53.06% |
| Median DD | 52.46% |
Description: CTMX CytomX Therapeutics December 29, 2025
CytomX Therapeutics (NASDAQ:CTMX) is an oncology-focused biopharma that leverages its conditional-activation PROBODY platform to create antibodies that become active only within the tumor microenvironment, aiming to broaden the therapeutic window for ADCs, T-cell engagers, and cytokine therapies.
Current lead assets include CX-904 (an EGFR-directed T-cell-engaging bispecific), CX-2051 (a conditional ADC against EpCAM for colorectal and other epithelial cancers), and CX-801 (a PROBODY-masked interferon-α2b cytokine). The pipeline also contains CX-2029 (CD71-targeted ADC) and a PROBODY version of non-fucosylated ipilimumab (BMS-986288) in collaboration with Bristol Myers Squibb.
Strategic partnerships span Amgen, Astellas, Regeneron, Moderna, and a clinical-trial supply agreement with Merck to test CX-801 alongside KEYTRUDA (pembrolizumab). These collaborations provide non-dilutive funding and de-risk development, but the company remains early-stage with no commercial products.
As of the latest filing (Q3 2024), CytomX reported cash and equivalents of roughly $140 million, giving it an estimated 18-month runway at current burn rates; the biotech sector’s ADC market is projected to grow at a CAGR of ~15% through 2030, a macro driver that could lift the valuation of conditional-activation technologies if clinical milestones are met.
For anyone building a deeper thesis on CTMX, a quick look at ValueRay’s analyst notes may surface additional quantitative insights worth exploring.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (28.0m TTM) > 0 and > 6% of Revenue (6% = 6.82m TTM) |
| FCFTA -0.46 (>2.0%) and ΔFCFTA 18.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 95.21% (prev 3.91%; Δ 91.30pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.46 (>3.0%) and CFO -72.3m <= Net Income 28.0m (YES >=105%, WARN >=100%) |
| Net Debt (-28.6m) to EBITDA (26.1m) ratio: -1.09 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (165.0m) change vs 12m ago 93.66% (target <= -2.0% for YES) |
| Gross Margin 99.33% (prev 98.88%; Δ 0.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 76.46% (prev 91.10%; Δ -14.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.26 (EBITDA TTM 26.1m / Interest Expense TTM -3.42m) >= 6 (WARN >= 3) |
Altman Z'' -22.54
| (A) 0.68 = (Total Current Assets 149.2m - Total Current Liabilities 41.0m) / Total Assets 158.3m |
| (B) -4.31 = Retained Earnings (Balance) -682.4m / Total Assets 158.3m |
| warn (B) unusual magnitude: -4.31 — check mapping/units |
| (C) 0.17 = EBIT TTM 24.8m / Avg Total Assets 148.6m |
| (D) -13.41 = Book Value of Equity -682.3m / Total Liabilities 50.9m |
| Total Rating: -22.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.52
| 1. Piotroski 3.0pt |
| 2. FCF Yield -12.43% |
| 3. FCF Margin -63.67% |
| 4. Debt/Equity 0.05 |
| 5. Debt/Ebitda -1.09 |
| 6. ROIC - WACC (= 25.15)% |
| 7. RoE 44.49% |
| 8. Rev. Trend 20.55% |
| 9. EPS Trend 69.61% |
What is the price of CTMX shares?
Over the past week, the price has changed by +23.91%, over one month by +26.82%, over three months by +64.33% and over the past year by +536.29%.
Is CTMX a buy, sell or hold?
- Strong Buy: 2
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CTMX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.1 | 64.4% |
| Analysts Target Price | 7.1 | 64.4% |
| ValueRay Target Price | 4.8 | 12.3% |
CTMX Fundamental Data Overview January 17, 2026
P/E Forward = 14.2045
P/S = 6.3372
P/B = 6.7055
P/EG = -1.8
Revenue TTM = 113.6m USD
EBIT TTM = 24.8m USD
EBITDA TTM = 26.1m USD
Long Term Debt = 5.60m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.60m USD (from shortTermDebt, last quarter)
Debt = 5.60m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.6m USD (from netDebt column, last quarter)
Enterprise Value = 582.1m USD (720.1m + Debt 5.60m - CCE 143.6m)
Interest Coverage Ratio = -7.26 (Ebit TTM 24.8m / Interest Expense TTM -3.42m)
EV/FCF = -8.05x (Enterprise Value 582.1m / FCF TTM -72.4m)
FCF Yield = -12.43% (FCF TTM -72.4m / Enterprise Value 582.1m)
FCF Margin = -63.67% (FCF TTM -72.4m / Revenue TTM 113.6m)
Net Margin = 24.66% (Net Income TTM 28.0m / Revenue TTM 113.6m)
Gross Margin = 99.33% ((Revenue TTM 113.6m - Cost of Revenue TTM 760.0k) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 98.14%)
Tobins Q-Ratio = 3.68 (Enterprise Value 582.1m / Total Assets 158.3m)
Interest Expense / Debt = 41.85% (Interest Expense 2.34m / Debt 5.60m)
Taxrate = 0.70% (224.0k / 32.1m)
NOPAT = 24.7m (EBIT 24.8m * (1 - 0.70%))
Current Ratio = 3.64 (Total Current Assets 149.2m / Total Current Liabilities 41.0m)
Debt / Equity = 0.05 (Debt 5.60m / totalStockholderEquity, last quarter 107.4m)
Debt / EBITDA = -1.09 (Net Debt -28.6m / EBITDA 26.1m)
Debt / FCF = 0.40 (negative FCF - burning cash) (Net Debt -28.6m / FCF TTM -72.4m)
Total Stockholder Equity = 63.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.85% (Net Income 28.0m / Total Assets 158.3m)
RoE = 44.49% (Net Income TTM 28.0m / Total Stockholder Equity 63.0m)
RoCE = 36.23% (EBIT 24.8m / Capital Employed (Equity 63.0m + L.T.Debt 5.60m))
RoIC = 39.17% (NOPAT 24.7m / Invested Capital 63.0m)
WACC = 14.02% (E(720.1m)/V(725.7m) * Re(13.81%) + D(5.60m)/V(725.7m) * Rd(41.85%) * (1-Tc(0.01)))
Discount Rate = 13.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 56.57%
Fair Price DCF = unknown (Cash Flow -72.4m)
EPS Correlation: 69.61 | EPS CAGR: 64.06% | SUE: 0.73 | # QB: 0
Revenue Correlation: 20.55 | Revenue CAGR: -27.32% | SUE: -0.76 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.36 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=-1403.4% | Growth Revenue=-63.0%
Additional Sources for CTMX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle